Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Mattsson, Johanna M ^a   Ravela, Suvi ^a   Hekim, Can ^a   Jonsson, Magnus ^b   Malm, Johan ^b   Närvänen, Ale ^c   Stenman, Ulf Håkan ^a   Koistinen, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ENTACTIN; FIBRONECTIN; GALECTIN 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5C7; PEPTIDES AND PROTEINS; PLASMINOGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN B2; PROTEIN C4; SEMENOGELIN I; SEMENOGELIN II; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIGEN BINDING; ANTIGEN FUNCTION; ARTICLE; BINDING AFFINITY; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME KINETICS; HUMAN; HUMAN CELL; MALE; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN DETERMINATION; KINETICS; METABOLISM; PHYSIOLOGY; PROSTATE; UMBILICAL VEIN ENDOTHELIAL CELL;

FIBRONECTINS; GALECTIN 3; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROTEOLYSIS;

EID: 84907202498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107819     Document Type: Article

References (75)

1. Mason SD, Joyce JA (2011) Proteolytic networks in cancer. Trends Cell Biol 21: 228-237.
2. Lopez-Otin C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808.
3. Lopez-Otin C, Hunter T (2010) The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 10: 278-292.
4. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD (2012) Targeting proteinase-activated receptors: Therapeutic potential and challenges. Nat Rev Drug Discov 11: 69-86.
5. Drag M, Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9: 690-701.
6. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
7. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141: 52-67.
8. Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4: 876-890.
9. Lawrence MG, Lai J, Clements JA (2010) Kallikreins on steroids: Structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31: 407-446.
10. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, et al. (2005) Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl (216): 64-81.
11. Veveris-Lowe TL, Kruger SJ, Walsh T, Gardiner RA, Clements JA (2007) Seminal fluid characterization for male fertility and prostate cancer: Kallikreinrelated serine proteases and whole proteome approaches. Semin Thromb Hemost 33: 87-99.
12. Lilja H, Ulmert D, Vickers AJ (2008) Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 8: 268-278.
13. Koistinen H, Stenman UH (2012) PSA (prostate-specific antigen) and other kallikrein-related peptidases in prostate cancer. In: Magdolen V, Sommerhoff CP, Fritz H, Schmitt M, editors. Kallikrein-related peptidases, Volume 2: Novel cancer-related biomarkers. Berlin, Boston: De Gruyter. pp. 61-81.
14. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R (1986) Human prostatespecific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 83: 3166-3170.
15. Christensson A, Laurell CB, Lilja H (1990) Enzymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763.
16. Lilja H (1985) A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899-1903.
17. Lilja H, Abrahamsson PA, Lundwall A (1989) Semenogelin, the predominant protein in human semen. primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 264: 1894-1900.
18. de Lamirande E (2007) Semenogelin, the main protein of the human semen coagulum, regulates sperm function. Semin Thromb Hemost 33: 60-68.
19. Fortier AH, Nelson BJ, Grella DK, Holaday JW (1999) Antiangiogenic activity of prostate-specific antigen.see comment. J Natl Cancer Inst 91: 1635-1640.
20. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, et al. (1999) Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81: 1269-1273.
21. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, et al. (2003) Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56: 212-219.
22. Mattsson JM, Laakkonen P, Stenman UH, Koistinen H (2009) Antiangiogenic properties of prostate-specific antigen (PSA). Scand J Clin Lab Invest 69: 447-451.
23. Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H (2008) Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 68: 945-954.
24. Lilja H, Oldbring J, Rannevik G, Laurell CB (1987) Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 80: 281-285.
25. Webber MM, Waghray A, Bello D (1995) Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1: 1089-1094.
26. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, et al. (2004) Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 207: 79-87.
27. Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979.
28. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH (2000) Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 267: 6212-6220.
29. Mattsson JM, Narvanen A, Stenman UH, Koistinen H (2012) Peptides binding to prostate-specific antigen enhance its antiangiogenic activity. Prostate 72: 1588-1594.
30. Koistinen H, Narvanen A, Pakkala M, Hekim C, Mattsson JM, et al. (2008) Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem 389: 633-642.
31. Fox JW, Mayer U, Nischt R, Aumailley M, Reinhardt D, et al. (1991) Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. EMBO J 10: 3137-3146.
32. Wu P, Stenman UH, Pakkala M, Narvanen A, Leinonen J (2004) Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 58: 345-353.
33. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH (1995) Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 41: 1567-1573.
34. Malm J, Hellman J, Magnusson H, Laurell CB, Lilja H (1996) Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem 238: 48-53.
35. Koistinen H, Hekim C, Wu P, Narvanen A, Stenman UH (2014) Evaluation of peptides as protease inhibitors and stimulators. Methods Mol Biol 1088: 147-158.
36. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, et al. (1997) Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 57: 4924-4930.
37. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
38. Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, et al. (1999) Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostatespecific antigen. Tumour Biol 20: 1-12.
39. Manning ML, Kostova M, Williams SA, Denmeade SR (2012) Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid. Prostate 72: 1233-1238.
40. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
41. Matsudaira P (1987) Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 262: 10035-10038.
42. Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, et al. (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21: 3666-3672.
43. Koistinen H, Seppala M, Koistinen R (1994) Different forms of insulin-like growth factor-binding protein-3 detected in serum and seminal plasma by immunofluorometric assay with monoclonal antibodies. Clin Chem 40: 531-536.
44. Koistinen H, Paju A, Koistinen R, Finne P, Lovgren J, et al. (2002) Prostatespecific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50: 112-118.
45. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, et al. (1998) Substrate specificity of prostate-specific antigen (PSA). Chem Biol 5: 475-488.
46. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H (2013) Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. established relevance and emerging roles. Thromb Haemost 110: 484-492.
47. Hsieh MC, Cooperman BS (2000) The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA). Biochim Biophys Acta 1481: 75-87.
48. Stenman UH, Leinonen J, Zhang WM, Finne P (1999) Prostate-specific antigen. Semin Cancer Biol 9: 83-93.
49. Stenman UH (1997) Prostate-specific antigen, clinical use and staging: An overview. Br J Urol 79 Suppl 1: 53-60.
50. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB (1988) Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12: 39-46.
51. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, et al. (2007) Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 52: 1670-1679.
52. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT (2001) Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48: 1-6.
53. Jonsson M, Lundwall A, Malm J (2006) The semenogelins: Proteins with functions beyond reproduction? Cell Mol Life Sci 63: 2886-2888.
54. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, et al. (1992) Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053.
55. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, et al. (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J-Pathol 156: 899-909.
56. Saraswati S, Block AS, Davidson MK, Rank RG, Mahadevan M, et al. (2011) Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate 71: 197-208.
57. Hohenester E, Yurchenco PD (2013) Laminins in basement membrane assembly. Cell Adh Migr 7: 56-63.
58. Mayer U, Mann K, Timpl R, Murphy G (1993) Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. Eur J Biochem 217: 877-884.
59. Sires UI, Griffin GL, Broekelmann TJ, Mecham RP, Murphy G, et al. (1993) Degradation of entactin by matrix metalloproteinases. susceptibility to matrilysin and identification of cleavage sites. J Biol Chem 268: 2069-2074.
60. Titz B, Dietrich S, Sadowski T, Beck C, Petersen A, et al. (2004) Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1. Cell Mol Life Sci 61: 1826-1833.
61. Sage J, Leblanc-Noblesse E, Nizard C, Sasaki T, Schnebert S, et al. (2012) Cleavage of nidogen-1 by cathepsin S impairs its binding to basement membrane partners. PLoS One 7: e43494.
62. Ho MS, Bose K, Mokkapati S, Nischt R, Smyth N (2008) Nidogens-extracellular matrix linker molecules. Microsc Res Tech 71: 387-395.
63. Malm J, Hellman J, Hogg P, Lilja H (2000) Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by zn(2+), a tightbinding inhibitor. Prostate 45: 132-139.
64. Paju A, Bjartell A, Zhang WM, Nordling S, Borgstrom A, et al. (2000) Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol 157: 2011-2021.
65. Shaw JL, Diamandis EP (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53: 1423-1432.
66. LeBeau AM, Kostova M, Craik CS, Denmeade SR (2010) Prostate-specific antigen: An overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol Chem 391: 333-343.
67. Rawlings ND, Barrett AJ, Bateman A (2012) MEROPS: The database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 40: D343-50.
68. Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, et al. (2006) Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem 281: 25678-25688.
69. Ries A, GohringW, Fox JW, Timpl R, Sasaki T (2001) Recombinant domains of mouse nidogen-1 and their binding to basement membrane proteins and monoclonal antibodies. Eur J Biochem 268: 5119-5128.
70. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, et al. (1997) The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 94: 10868-10872.
71. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, et al. (1998) Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 95: 5579-5583.
72. Markowska AI, Liu FT, Panjwani N (2010) Galectin-3 is an important mediator of VEGF-and bFGF-mediated angiogenic response. J Exp Med 207: 1981-1993.
73. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, et al. (2010) Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116: 4025-4033.
74. Pakkala M, Jylhasalmi A, Wu P, Leinonen J, Stenman UH, et al. (2004) Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity. J Pept Sci 10: 439-447.
75. Harkonen HH, Mattsson JM, Maatta JA, Stenman UH, Koistinen H, et al. (2011) The discovery of compounds that stimulate the activity of kallikreinrelated peptidase 3 (KLK3). ChemMedChem 6: 2170-2178.